ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has announced its participation in two major investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 11:00 a.m. ET, and the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. GMT. Both presentations will feature CEO Ameet Mallik in fireside chat formats. Live webcasts will be available on the company's investor relations website, with replays accessible for approximately 30 days after each event.
ADC Therapeutics (NYSE: ADCT), un leader nel settore commerciale con focus su coniugati di farmaci ad anticorpi, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo novembre. L'azienda presenterà alla Guggenheim Securities Healthcare Innovation Conference l'11 novembre 2024, alle 11:00 ET, e alla Jefferies London Healthcare Conference il 19 novembre 2024, alle 11:00 GMT. Entrambe le presentazioni presenteranno il CEO Ameet Mallik in formato chiacchierata informale. Saranno disponibili webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, con le registrazioni accessibili per circa 30 giorni dopo ogni evento.
ADC Therapeutics (NYSE: ADCT), un líder en la etapa comercial en conjugados de fármacos con anticuerpos, ha anunciado su participación en dos importantes conferencias de inversores este noviembre. La empresa presentará en la Guggenheim Securities Healthcare Innovation Conference el 11 de noviembre de 2024, a las 11:00 a.m. ET, y en la Jefferies London Healthcare Conference el 19 de noviembre de 2024, a las 11:00 a.m. GMT. Ambas presentaciones contarán con el CEO Ameet Mallik en formato de charla informal. Se ofrecerán transmisiones en vivo en el sitio web de relaciones con inversores de la empresa, con repeticiones accesibles durante aproximadamente 30 días después de cada evento.
ADC Therapeutics (NYSE: ADCT)는 항체 약물 접합체의 상업적 선두주자로서 이번 11월에 두 개의 주요 투자자 회의에 참가할 것이라고 발표했습니다. 회사는 2024년 11월 11일 오전 11시 ET에 구겐하임 증권 의료 혁신 회의에서 발표하고, 2024년 11월 19일 오전 11시 GMT에 제프리스 런던 의료 회의에서 발표할 예정입니다. 두 프레젠테이션 모두 Ameet Mallik CEO가 대화 형식으로 진행합니다. 생중계는 회사의 투자자 관계 웹사이트에서 제공되며, 각 이벤트 후 약 30일 동안 다시 볼 수 있습니다.
ADC Therapeutics (NYSE: ADCT), un leader en phase commerciale dans le domaine des conjugués de médicaments à anticorps, a annoncé sa participation à deux grandes conférences pour investisseurs en novembre. La société fera une présentation à la Guggenheim Securities Healthcare Innovation Conference le 11 novembre 2024 à 11h00 ET, et à la Jefferies London Healthcare Conference le 19 novembre 2024 à 11h00 GMT. Les deux présentations mettront en vedette le PDG Ameet Mallik dans des formats de discussions informelles. Des retransmissions en direct seront disponibles sur le site des relations avec les investisseurs de l'entreprise, avec des rediffusions accessibles pendant environ 30 jours après chaque événement.
ADC Therapeutics (NYSE: ADCT), ein führendes Unternehmen in der kommerziellen Phase von Antikörper-Wirkstoff-Konjugaten, hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im November angekündigt. Das Unternehmen wird am 11. November 2024 um 11:00 Uhr ET auf der Guggenheim Securities Healthcare Innovation Conference präsentieren und am 19. November 2024 um 11:00 Uhr GMT auf der Jefferies London Healthcare Conference. Beide Präsentationen werden vom CEO Ameet Mallik im Rahmen von Informal Talks gestaltet. Live-Webcasts werden auf der Investorenbeziehungswebsite des Unternehmens verfügbar sein, mit Zugriff auf Aufzeichnungen für etwa 30 Tage nach jeder Veranstaltung.
- None.
- None.
Guggenheim Securities Healthcare Innovation Conference
Date: November 11, 2024
Presentation Time: 11:00 a.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Jefferies London Healthcare Conference
Date: November 19, 2024
Presentation Time: 11:00 a.m. GMT
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-present-at-november-investor-conferences-302294663.html
SOURCE ADC Therapeutics SA
FAQ
When is ADC Therapeutics (ADCT) presenting at the Guggenheim Securities Healthcare Conference in 2024?
What time is ADCT's presentation at the Jefferies London Healthcare Conference 2024?
How long will the webcasts of ADCT's November 2024 investor presentations be available?
What format will ADCT's presentations take at the November 2024 investor conferences?
